Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds

Patent Citations (13)

Non-Patent Literature (54)

• Apostolides, Z., et al., “Inhibition of PhIP mutagenicity by catechins, and by theaflavins and gallate esters,” Mutation Research, 389(2-3):167-172 (1997).Applicant
• Baer-Dubowska, W., et al., “Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds,” Xenobiotica, 28(8):735-43 (1998).Applicant
• Bamforth, K.J., et al., “Common food additives are potent inhibitors of human liver 17α-ethinyloestradiol and dopamine sulphotransferases,” Biochem. Pharmacol., 46(10):1713-1720 (1993).Applicant
• Bonkovsky et al., “Cytochrome P450 of Small Intestinal Epithelial Cells,” Gastroenterology, 88:458-467 (1985).Applicant
• Bourri{acute over (e)}, M., et al., “Cytochrome P450 Isoform Inhibitors as a Tool for the Investigation of Metabolic Reactions Catalyzed by Human Liver Microsomes,” J. Pharmacol. Exp. Ther., 277(1):321-332 (1996).Applicant
• Bradford, M.M., “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding,” Anal. Biochem., 72:248-254 (1976).Applicant
• Burke, M. D., et al., “Ethoxy-, Pentoxy and Benzyloxyphenoxazones and Homologues: A Series Of Substrates To Distinguish Between Different Induced Cytochromes P-450,” Biochem. Pharmacol., 34(18):337-3345 (1985).Applicant
• Clarke, S.E., et al., “Characterization of the inhibition of P4501A2 by furafylline,” Xenobiotica, 24:517-26 (1994).Applicant
• Fabre, G., et al., “Evidence of CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions,” Drug Metab. Dispos., 21(6):978-985 (1993).Applicant
• Fasco et al., “Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism,” Mol. Pharmacol., 43:226-233 (1993).Applicant
• Gonzalez, F.J., et al., “Human P450PCN1: Sequence, Chromosome Localization, and Direct Evidence through cDNA Expression That P450PCN1 Is Nifedipine Oxidase, DNA,” 7(2):79-86 (1988).Applicant
• Greenblatt, David J., “Presystemic Extraction: Mechanisms and Consequences,” J. Clin. Pharmacol., 33:650-656 (1993).Applicant
• Kaminsky et al., “Small Intestinal Cytochromes P450,” Toxicology, 21(6):407-422 (1992).Applicant
• Kedderis, G.L., et al., “Characterization of the N-Demethylation Reactions Catalyzed by Chloroperoxidase,” Microsomes, Drug Oxic., Chem. Carcinoq., Int. Symp. Microsomes Drug Oxid., 1:351-4, pub. Academic Press, eds. Coon, et al. (1980).Applicant
• Kedderis, G.L., et al., “N-Demethylation Reactions Catalyzed by Chloroperoxidase,” J. Biol. Chem., 255(21):10174-82 (1980).Applicant
• Kelleher, J ., et al., “Modification of Paracetamol Hepatotoxicity by Anti-Oxidants,” J. Ind. Med. Res., 4 suppl. (4):138-144 (1976).Applicant
• Kelleher, J., et al., “Modifications of Paracetamol Toxicity by Antioxidants,” Biochem. Soc. Transact., 4:292-294 (1976).Applicant
• Kivistö, K.T., et al., “Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole,” Clin. Pharmacol. Ther., 62(3):348-354 (1997).Applicant
• Kolars, J.C. et al., “Identification of Rifampin-Inducible P450III A4 (CYP3A4) in Human Small Bowel Enterocytes,” J. Clin. Investig., 90:1871-1878 (1992).Applicant
• Kolars et al., “Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia,” Gastroenterology, 102:1188-1198 (1992).Applicant
• Komori et al., “Cytochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization,” J. Biochem., 104:912-16 (1988).Applicant
• Kronbach et al., “Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P-450III Gene Family as the Major Cyclosporine-Metabolizing Enzyme Explains Interactions of Cyclosprine with Other Drugs,” Clin. Pharmacol. Ther., 43(6):630-5 (1988).Applicant
• Leemann, T., et al., “Cytochrome P450TB (CYP2C): A Major Monooxygenase Catalyzing Diclofenac 4′-Hydroxylation in Human Liver,” Life Sciences, 52:29-34 (1992).Applicant
• Lilja, J.J., et al., “Grapefruit juice substantially increases plasma concentrations of buspirone,” Clin. Pharmacol. Ther., 64(6);655-660 (1998).Applicant
• Lown, K.S., et al., “Sequences of Intestinal and Hepatic Cytochrome P450 3A4 cDNAs are Identical,” Drug Metab. Dispos., 26(2):185-187 (1998).Applicant
• Lucas, D., et al., “Chlorzoxazone: An in Vitro and in Vivo Substrate Probe for Liver CYP2E1,” Methods in Enzymology, 272:115-123 (1996).Applicant
• Miller, C. et al., “Modulation of the mutagenicity and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-3(3-pyridyl)-1-butanone (NNK) by phenolic compounds,” Mutation Research, 368(3-4)221-233 (1996).Applicant
• Nash, “The Colorimetic Estimation of Formaldehyde by Means of the Hantzach Reaction,” Biochem. J., 55:416-421 (1953).Applicant
• Nelson, D. R., et al., “P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature,” Pharmacogenetics, 6:1-42 (1996).Applicant
• Newton, D.J., et al., “Cytochrome P450 Inhibitors: Evaluation of Specificities in the In Vitro Metabolism of Therapeutic Agents by Human Liver Microsomes,” Drug Metabolism and Disposition, 23(1):154-158 (1995).Applicant
• Omura, T., et al., “The Carbon Monoxide-Binding Pigment of Liver Microsomes II. Solubilization, Purification and Properties,” J. Biol. Chem., 239:2370-2378 (1964).Applicant
• Schmiedlin-Ren et al., “Cultured Adult Rat Jejunal Explants as a Model for Studying Regulation of CYP3A,” Biochem. Pharmacol., 46(5):905-918 (1993).Applicant
• Somberg et al., “The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the 1990's,” J. Clin. Pharmacol., 33:670-673 (1993).Applicant
• Straehl, P., et al., “Isosorbide 5-Mononitrate and Isosorbide 2-Mononitrate Kinetics after Intravenous and Oral Dosing,” Clin. Pharmacol. Ther., 36(4):485-492 (1985).Applicant
• Straehl, P., et al., “Isosorbide Dinitrate Bioavailability, Kinetics, and Metabolism,” Clin. Pharmacol. Ther., 38(2):140-149 (1985).Applicant
• Stuckey, Ben N., “Antioxidants as Food Stabilizers,” CRC Handbook of Food Additives, 2nd ed., pp. 185-199 (1980).Applicant
• Tam, Yun K., “Individual Variation in First-Pass Metabolism,” Clin. Pharmacokinet, 25(4):300-328 (1993).Applicant
• Trivier et al., “Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report),” Life Sci., 52:PL91-96 (1993).Applicant
• van Hoogdalem et al., “Intestinal Drug Absorbtion Enhancement: An Overview,” Pharmacol. Ther., 44:407-443 (1989).Applicant
• Wacher, V. J., et al., “Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics,” Journal of Pharmaceutical Sciences 87(11):1322-1330(1998).Applicant
• Watkins et al., “Identification of Glucocorticoid-Inducible Cytochromes P-450 in the Intestinal Mucosa of Rats and Man,” J. Clin. Invest., 80:1029-36 (1987).Applicant
• Watkins et al., “The Role of Cytochromes P450 in Cyclosporine Metabolism,” J. Am. Acad. Dermacol., 23:1301-1309 (1990).Applicant
• Watkins et al., “Drug Metabolism by Cytochromes P450 in the Liver and Small Bowel,” Gastrointestinal Pharmacology, 21(3):511-527 (1992).Applicant
• Weinke, S., et al., “Effect of four synthetic antioxidants on the formations of ethylene from methional in rat liver microsomes,” Toxicology Letters, 35:247-251 (1987).Applicant
• WHO Food Additives Series, vol. 32:3-23 (1993), Abstract.Applicant
• World Health Organization, “Evaluation of certain food additives and contaminants,” Pamphlet #837, pp.6-7, Geneva (1993).Applicant
• Wrighton et al., “Demonstration in Multiple Species of Inducible Hepatic Cytochromes P-450 and their mRNAs Related to the Glucocorticoid-Inducible Cytochrome P-450 of the Rat,” Molecular Pharmacology, 28:312-321 (1985).Applicant
• Wrighton et al., “Studies on the Expression and Metabolic Capabilities of Human Liver Cytochrome P450IIIA5 (HLp3),” Mol. Pharmacol., 38:207-213 (1990).Applicant
• Wu et al., “Use of IV and Oral Drug Levels from Cyclosporine (CsA) with Concomitant Rifampin to Differentiate Gut Absorption and Metabolism,” Pharm. Res. 10; Abstract #PPDM 8185 (1993).Applicant
• Yang et al., “Inhibitions of Hepatic Mixed Function Oxidase Activity by Propyl Gallate,” Biochem. Pharmacol., 23:3129-3138 (1974).Applicant
• Abstract for Japanese Patent No. JP 0220 2813 A JP, (Aug. 28, 1993).Applicant
• Abstract for Japanese Patent No. JP 0220 2813 A2, (Aug. 10, 1990).Applicant
• Obermeier et al., “Effects of Bioflavonoids on Hepatic P450 Activities,” Xenobiotica, 25(6):575-584, (1995).Applicant
• Wang et al., “Interaction of Epicatechins Derived from Green Tea with Rat Hepatic Cytochrome P-450,” Drug Metabolism and Disposition, 16(1):98-103, (1988).Applicant